Colchicine aggravates coxsackievirus B3 infection in mice

International Journal of Cardiology

Volumn 216, Issue , 2016, Pages 58-65

  Smilde, Bernard J ^a   Woudstra, Linde ^a,b   Fong Hing, Gene ^a   Wouters, Diana ^c   Zeerleder, Sacha ^c,d   Murk, Jean Luc ^e   Van Ham, Marieke ^c   Heymans, Stephane ^f   Juffermans, Lynda J M ^a,b   Van Rossum, Albert C ^a,b   Niessen, Hans W M ^a,b   Krijnen, Paul A J ^a,b   Emmens, Reindert W ^a,b,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SANQUIN RESEARCH   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Colchicine; Coxsackievirus B3; Mouse; Myocarditis

Indexed keywords

COLCHICINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS INFECTION; COXSACKIEVIRUS B3; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; HEART; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MEGAKARYOCYTE; MORTALITY; MOUSE; MOUSE MODEL; NEUTROPHIL COUNT; NONHUMAN; PANCREAS; PANCREAS INJURY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPLEEN; VIRUS LOAD; VIRUS MYOCARDITIS; ANIMAL; C3H MOUSE; COXSACKIEVIRUS INFECTIONS; DISEASE MODEL; DRUG EFFECTS; ENTEROVIRUS B; HUMAN; MYOCARDITIS; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; COLCHICINE; COXSACKIEVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; ENTEROVIRUS B, HUMAN; HEART; HUMANS; MALE; MICE; MICE, INBRED C3H; MYOCARDITIS; PANCREAS; SPLEEN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84964664176     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.04.144     Document Type: Article

References (30)

1. A.L. Caforio, S. Pankuweit, E. Arbustini, and et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Eur. Heart J. 34 2013 2636 2648
2. A. Frustaci, C. Chimenti, F. Calabrese, M. Pieroni, G. Thiene, and A. Maseri Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders Circulation 107 2003 857 863
3. A. Frustaci, M.A. Russo, and C. Chimenti Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study Eur. Heart J. 30 2009 1995 2002
4. J.W. Mason, J.B. O'Connell, A. Herskowitz, and et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators N. Engl. J. Med. 333 1995 269 275
5. L. Andreoletti, N. Leveque, C. Boulagnon, C. Brasselet, and P. Fornes Viral causes of human myocarditis Arch. Cardiovasc. Dis. 102 2009 559 568
6. S. Deftereos, G. Giannopoulos, N. Papoutsidakis, and et al. Colchicine and the heart: pushing the envelope J. Am. Coll. Cardiol. 62 2013 1817 1825
7. G. Nuki, and P.A. Simkin A concise history of gout and hyperuricemia and their treatment Arthritis Res. Ther. 8 Suppl. 1 2006 S1
8. M. Imazio Colchicine for pericarditis Trends Cardiovasc. Med. 25 2015 129 136
9. M.M. LeWinter Clinical practice. Acute pericarditis N. Engl. J. Med. 371 2014 2410 2416
10. F.R. Abu, S. Banai, U. Chorin, O. Rogowski, G. Keren, and A. Roth Diagnostic yield of extensive infectious panel testing in acute pericarditis Cardiology 119 2011 134 139
11. N. Gultekin, and E. Kucukates Microtubule inhibition therapy by colchicine in severe myocarditis especially caused by Epstein-Barr and cytomegalovirus co-infection during a two-year period: a novel therapeutic approach J. Pak. Med. Assoc. 64 2014 1420 1423
12. B. Maisch, P.M. Seferovic, A.D. Ristic, and et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; the task force on the diagnosis and management of pericardial diseases of the European society of cardiology Eur. Heart J. 25 2004 587 610
13. S.J. Schnitt, P.S. Ciano, and F.J. Schoen Quantitation of lymphocytes in endomyocardial biopsies: use and limitations of antibodies to leukocyte common antigen Hum. Pathol. 18 1987 796 800
14. M. Nijhuis, M.N. van, R. Schuurman, and et al. Rapid and sensitive routine detection of all members of the genus enterovirus in different clinical specimens by real-time PCR J. Clin. Microbiol. 40 2002 3666 3670
15. C.E. Redon, A.J. Nakamura, Y.W. Zhang, and et al. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers Clin. Cancer Res. 16 2010 4532 4542
16. M. Imazio, D.H. Spodick, A. Brucato, R. Trinchero, and Y. Adler Controversial issues in the management of pericardial diseases Circulation 121 2010 916 928
17. J. Soler-Soler, J. Sagrista-Sauleda, and G. Permanyer-Miralda Relapsing pericarditis Heart 90 2004 1364 1368
18. B.N. Cronstein, Y. Molad, J. Reibman, E. Balakhane, R.I. Levin, and G. Weissmann Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils J. Clin. Invest. 96 2 1995 994 1002
19. N. Perico, D. Ostermann, M. Bontempeill, and et al. Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation J. Am. Soc. Nephrol. 7 1996 594 601
20. F. Martinon, V. Petrilli, A. Mayor, A. Tardivel, and J. Tschopp Gout-associated uric acid crystals activate the NALP3 inflammasome Nature 440 2006 237 241
21. E.W. Chia, R. Grainger, and J.L. Harper Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine Br. J. Pharmacol. 153 2008 1288 1295
22. A.H. Ding, F. Porteu, E. Sanchez, and C.F. Nathan Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents J. Exp. Med. 171 1990 715 727
23. G. Manukyan, M. Petrek, Z. Navratilova, S. Margaryan, and A. Boyajyan Transcriptional activity of neutrophils exposed to high doses of colchicine: short communication J. Biol. Regul. Homeost. Agents 29 2015 125 130
24. E.S. Razvi, Z. Jiang, B.A. Woda, and R.M. Welsh Lymphocyte apoptosis during the silencing of the immune response to acute viral infections in normal, lpr, and Bcl-2-transgenic mice Am. J. Pathol. 147 1 1995 79 91
25. N.L. Yates, R.D. Yammani, and M.A. Alexander-Miller Dose-dependent lymphocyte apoptosis following respiratory infection with vaccinia virus Virus Res. 137 2 2008 198 205
26. B. Yanagawa, O.B. Spiller, D.G. Proctor, and et al. Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice J. Infect. Dis. 189 8 2004 1431 1439
27. D.H. Craig, C.R. Owen, W.C. Conway, M.F. Walsh, C. Downey, and M.D. Basson Colchicine inhibits pressure-induced tumor cell implantation within surgical wounds and enhances tumor-free survival in mice J. Clin. Invest. 118 9 2008 3170 3180
28. G. Feng, and N. Kaplowitz Colchicine protects mice from the lethal effect of an agonistic anti-Fas antibody J. Clin. Invest. 105 3 2000 329 339
29. R.N. Reddy, J.R. Latendresse, and H.M. Mehendale Colchicine antimitosis causes progression of S-(1,2-dichlorovinyl)-l-cysteine-induced injury leading to acute renal failure and death in mice Toxicology 220 2-3 2006 147 159
30. T. Ueda, Y. Takeyama, M. Adachi, and et al. Effect of the microtubule-disrupting drug colchicine on rat cerulein-induced pancreatitis in comparison with the microtubule stabilizer taxol Pancreas 11 3 1995 294 302